IP Library › Granted Patent US 12,497,642
Granted Patent B2
US 12,497,642 · App. 16/629,211 · Granted Dec 16, 2025

Incorporation of unnatural nucleotides and methods of use in vivo thereof

Inventors: Floyd E. Romesberg (La Jolla, CA); Yorke Zhang (La Jolla, CA); Aaron W. Feldman (La Jolla, CA); Vivian T. Dien (La Jolla, CA)
Assignee: The Scripps Research Institute
C12P19/34C07H21/00C12N1/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,497,642
App. No.
16/629,211
Granted
Dec 16, 2025
Kind
B2
Abstract

Disclosed herein are in vivo methods, compositions, and kits for producing nucleic acids which comprises at least one unnatural base. Disclosed herein are in vivo methods of producing a nucleic acid with an expanded genetic alphabet, the method comprising incorporating at least one unnatural base in the nucleic acid. Disclosed herein are semi-synthetic organisms comprising an expanded genetic alphabet, wherein the genetic alphabet comprises at least one unnatural base. Disclosed herein are compositions that include a heterologous or recombinant polymerase and methods of use thereof. Further, disclosed herein are kits that are useful for stably incorporating an unnatural nucleic acid into a nucleic acid molecule, e.g., using the methods provided by the present invention in in vitro condition or under a cell free condition.

Claims (27)

1 . A method of producing DNA in an Escherichia coli , the method comprising incorporating into DNA present in an Escherichia coli at least a first unnatural base and the first unnatural base comprises:

and wherein the first unnatural base pairs with a second unnatural base to form an unnatural base pair (UBP), wherein the second unnatural base comprises,

and wherein the Escherichia coli expresses a nucleotide triphosphate transporter from Phaeodactylum tricornutum.

2 . The method of claim 1 , wherein the first unnatural base is bonded to an unnatural sugar moiety.

3 . The method of claim 2 , wherein the unnatural sugar moiety comprises a modification selected from:

(i) a modification at the 2′ position comprising:

(a) F; SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 F; O-alkyl, S-alkyl, N-alkyl; O-alkenyl, S-alkenyl, N-alkenyl; O-alkynyl, S-alkynyl, N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl is substituted or unsubstituted C 1 -C 10 alkyl, C 2 -C 10 alkenyl, and C 2 -C 10 alkynyl, respectively;

(b) —O[(CH 2 ) n O] m CH 3 , —O(CH 2 ) n OCH 3 , —O(CH 2 ) n NH 2 , —O(CH 2 ) n CH 3 , —O(CH 2 ) n —ONH 2 , or —O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , where n and m are each independently from 1 to 10; or (c) C 1 to C 10 alkyl, substituted C 1 to C 10 alkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 , substituted silyl, a reporter group, an intercalator, or a group for improving the pharmacokinetic properties of an oligonucleotide;

(ii) a modification at the 5′ position comprising: 5′-vinyl or 5′-methyl;

(iii) a modification at the 4′ position comprising: 4′-S; and

(iv) any combination thereof.

4 . An Escherichia coli expressing a nucleotide triphosphate transporter from Phaeodactylum tricornutum and comprising DNA that comprises at least a first unnatural base, wherein the first unnatural base comprises:

and wherein the first unnatural base pairs with a second unnatural base to form an unnatural base pair (UBP), wherein the second unnatural base comprises

5 . The Escherichia coli of claim 4 , wherein the first unnatural base is bonded to an unnatural sugar moiety.

6 . The Escherichia coli of claim 5 , wherein the unnatural sugar moiety comprises a modification selected from the group:

(i) a modification at the 2′ position comprising: (a) F; SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 F; O-alkyl, S-alkyl, N-alkyl; O-alkenyl,

S-alkenyl, N-alkenyl; O-alkynyl, S-alkynyl, N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl is substituted or unsubstituted C 1 -C 10 alkyl, C 2 -C 10 alkenyl, and C 2 -C 10 alkynyl, respectively; (b)

—O[(CH 2 ) n O] m CH 3 , —O(CH 2 ) n OCH 3 , —O(CH 2 ) n NH 2 , —O(CH 2 ) n CH 3 ,

—O(CH 2 ) n —ONH 2 , or —O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , where n and m are each independently from 1 to 10; or (c) C 1 to C 10 alkyl, substituted C 1 to C 10 alkyl SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 , substituted silyl, a reporter group, an intercalator, or a group for improving the pharmacokinetic properties of an oligonucleotide;

(ii) a modification at the 5′ position comprising: 5′-vinyl or

5′-methyl;

(iii) a modification at the 4′ position comprising: 4′-S,

and (iv) any combination thereof.

7 . A method of producing DNA in an Escherichia coli , the method comprising incorporating at least a first unnatural base into DNA present in an Escherichia coli cell expressing a nucleotide triphosphate transporter from Phaeodactylum tricornutum , wherein the first unnatural base comprises:

wherein the first unnatural base pairs with a second unnatural base to form an unnatural base pair (UBP) in the DNA, and wherein the second unnatural base comprises:

8 . An Escherichia coli expressing a nucleotide triphosphate transporter from Phaeodactylum tricornutum and comprising DNA that comprises at least a first unnatural base, wherein the first unnatural base comprises:

and wherein the first unnatural base pairs with a second unnatural base to form an unnatural base pair (UBP) in the DNA, and wherein the second unnatural base comprises:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2025
From: ROMESBERG, FLOYD E.; ZHANG, YORKE; FELDMAN, AARON W.; DIEN, VIVIAN T.
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 070958/0711 →
Continuity (2)
Provisional Application 62531329 · Jul 11, 2017
Related Publication 20200224234A1 · Jul 16, 2020
References Cited (400)
US 3687808A · Merigan, Jr. et al. · 1972 [cited by applicant]
US 4469863A · Ts et al. · 1984 [cited by applicant]
US 4476301A · Imbach et al. · 1984 [cited by applicant]
US 4587044A · Miller et al. · 1986 [cited by applicant]
US 4605735A · Miyoshi et al. · 1986 [cited by applicant]
US 4667025A · Miyoshi et al. · 1987 [cited by applicant]
US 4762779A · Snitman · 1988 [cited by applicant]
US 4789737A · Miyoshi et al. · 1988 [cited by applicant]
US 4824941A · Gordon et al. · 1989 [cited by applicant]
US 4828979A · Klevan et al. · 1989 [cited by applicant]
US 4835263A · Nguyen et al. · 1989 [cited by applicant]
US 4845205A · Huynh et al. · 1989 [cited by applicant]
US 4849513A · Smith et al. · 1989 [cited by applicant]
US 4876335A · Yamane et al. · 1989 [cited by applicant]
US 4904582A · Tullis · 1990 [cited by applicant]
US 4910300A · Urdea et al. · 1990 [cited by applicant]
US 4948882A · Ruth · 1990 [cited by applicant]
US 4958013A · Letsinger · 1990 [cited by applicant]
US 4981957A · Lebleu et al. · 1991 [cited by applicant]
US 5015733A · Smith et al. · 1991 [cited by applicant]
US 5023243A · Tullis · 1991 [cited by applicant]
US 5034506A · Summerton et al. · 1991 [cited by applicant]
US 5082830A · Brakel et al. · 1992 [cited by applicant]
US 5093232A · Urdea et al. · 1992 [cited by applicant]
US 5109124A · Ramachandran et al. · 1992 [cited by applicant]
US 5112963A · Pieles et al. · 1992 [cited by applicant]
US 5118800A · Smith et al. · 1992 [cited by applicant]
US 5118802A · Smith et al. · 1992 [cited by applicant]
US 5130302A · Spielvogel et al. · 1992 [cited by applicant]
US 5134066A · Rogers et al. · 1992 [cited by applicant]
US 5138045A · Cook et al. · 1992 [cited by applicant]
US 5166315A · Summerton et al. · 1992 [cited by applicant]
US 5175273A · Bischofberger et al. · 1992 [cited by applicant]
US 5177196A · Meyer, Jr. et al. · 1993 [cited by applicant]
US 5185444A · Summerton et al. · 1993 [cited by applicant]
US 5188897A · Suhadolnik et al. · 1993 [cited by applicant]
US 5214134A · Weis et al. · 1993 [cited by applicant]
US 5214136A · Lin et al. · 1993 [cited by applicant]
US 5216141A · Benner · 1993 [cited by applicant]
US 5218105A · Cook et al. · 1993 [cited by applicant]
US 5235033A · Summerton et al. · 1993 [cited by applicant]
US 5245022A · Weis et al. · 1993 [cited by applicant]
US 5254469A · Warren, III et al. · 1993 [cited by applicant]
US 5258506A · Urdea et al. · 1993 [cited by applicant]
US 5262536A · Hobbs, Jr. · 1993 [cited by applicant]
US 5264423A · Cohen et al. · 1993 [cited by applicant]
US 5264562A · Matteucci · 1993 [cited by applicant]
US 5264564A · Matteucci · 1993 [cited by applicant]
US 5272250A · Spielvogel et al. · 1993 [cited by applicant]
US 5276019A · Cohen et al. · 1994 [cited by applicant]
US 5278302A · Caruthers et al. · 1994 [cited by applicant]
US 5286717A · Cohen et al. · 1994 [cited by applicant]
US 5292873A · Rokita et al. · 1994 [cited by applicant]
US 5317098A · Shizuya et al. · 1994 [cited by applicant]
US 5319080A · Leumann · 1994 [cited by applicant]
US 5321131A · Agrawal et al. · 1994 [cited by applicant]
US 5359044A · Cook et al. · 1994 [cited by applicant]
US 5367066A · Urdea et al. · 1994 [cited by applicant]
US 5371241A · Brush · 1994 [cited by applicant]
US 5391723A · Priest · 1995 [cited by applicant]
US 5393878A · Leumann · 1995 [cited by applicant]
US 5399676A · Froehler · 1995 [cited by applicant]
US 5405938A · Summerton et al. · 1995 [cited by applicant]
US 5405939A · Suhadolnik et al. · 1995 [cited by applicant]
US 5414077A · Lin et al. · 1995 [cited by applicant]
US 5416203A · Letsinger · 1995 [cited by applicant]
US 5432272A · Benner · 1995 [cited by applicant]
US 5434257A · Matteucci et al. · 1995 [cited by applicant]
US 5446137A · Maag et al. · 1995 [cited by applicant]
US 5451463A · Nelson et al. · 1995 [cited by applicant]
US 5453496A · Caruthers et al. · 1995 [cited by applicant]
US 5455233A · Spielvogel et al. · 1995 [cited by applicant]
US 5457187A · Gmeiner et al. · 1995 [cited by applicant]
US 5459255A · Cook et al. · 1995 [cited by applicant]
US 5466677A · Baxter et al. · 1995 [cited by applicant]
US 5466786A · Buhr et al. · 1995 [cited by applicant]
US 5470967A · Huie et al. · 1995 [cited by applicant]
US 5476925A · Letsinger et al. · 1995 [cited by applicant]
US 5484908A · Froehler et al. · 1996 [cited by applicant]
US 5486603A · Buhr · 1996 [cited by applicant]
US 5489677A · Sanghvi et al. · 1996 [cited by applicant]
US 5502177A · Matteucci et al. · 1996 [cited by applicant]
US 5596086A · Matteucci et al. · 1997 [cited by applicant]
US 5596091A · Switzer · 1997 [cited by applicant]
US 5597696A · Linn et al. · 1997 [cited by applicant]
US 5597909A · Urdea et al. · 1997 [cited by applicant]
US 5599923A · Sessler et al. · 1997 [cited by applicant]
US 5599928A · Hemmi et al. · 1997 [cited by applicant]
US 5602240A · Mesmaeker et al. · 1997 [cited by applicant]
US 5608046A · Cook et al. · 1997 [cited by applicant]
US 5610289A · Cook et al. · 1997 [cited by applicant]
US 5610300A · Altmann et al. · 1997 [cited by applicant]
US 5614617A · Cook et al. · 1997 [cited by applicant]
US 5618704A · Sanghvi et al. · 1997 [cited by applicant]
US 5623070A · Cook et al. · 1997 [cited by applicant]
US 5625050A · Beaton et al. · 1997 [cited by applicant]
US 5627053A · Usman et al. · 1997 [cited by applicant]
US 5633360A · Bischofberger et al. · 1997 [cited by applicant]
US 5639873A · Barascut et al. · 1997 [cited by applicant]
US 5645985A · Froehler et al. · 1997 [cited by applicant]
US 5646265A · McGee · 1997 [cited by applicant]
US 5658873A · Bertsch-Frank et al. · 1997 [cited by applicant]
US 5663312A · Chaturvedula · 1997 [cited by applicant]
US 5670633A · Cook et al. · 1997 [cited by applicant]
US 5677437A · Teng et al. · 1997 [cited by applicant]
US 5677439A · Weis et al. · 1997 [cited by applicant]
US 5681941A · Cook et al. · 1997 [cited by applicant]
US 5700920A · Altmann et al. · 1997 [cited by applicant]
US 5714331A · Buchardt et al. · 1998 [cited by applicant]
US 5719262A · Buchardt et al. · 1998 [cited by applicant]
US 5750692A · Cook et al. · 1998 [cited by applicant]
US 5763588A · Matteucci et al. · 1998 [cited by applicant]
US 5830653A · Froehler et al. · 1998 [cited by applicant]
US 6005096A · Matteucci et al. · 1999 [cited by applicant]
US 6268490B1 · Imanishi et al. · 2001 [cited by applicant]
US 6525191B1 · Ramasamy · 2003 [cited by applicant]
US 6670461B1 · Wengel et al. · 2003 [cited by applicant]
US 6770748B2 · Imanishi et al. · 2004 [cited by applicant]
US 6794499B2 · Wengel et al. · 2004 [cited by applicant]
US 7034133B2 · Wengel et al. · 2006 [cited by applicant]
US 7053207B2 · Wengel · 2006 [cited by applicant]
US 7399845B2 · Seth et al. · 2008 [cited by applicant]
US 7427672B2 · Imanishi et al. · 2008 [cited by applicant]
US 10513706B2 · Romesberg et al. · 2019 [cited by applicant]
US 10626138B2 · Romesberg et al. · 2020 [cited by applicant]
US 10696719B2 · Romesberg et al. · 2020 [cited by applicant]
US 10696720B2 · Romesberg et al. · 2020 [cited by applicant]
US 11834479B2 · Romesberg · 2023 [cited by examiner]
US 11834689B2 · Ptacin · 2023 [cited by examiner]
US 20140328791A1 · Bossard et al. · 2014 [cited by applicant]
US 20170369871A1 · Ptacin et al. · 2017 [cited by applicant]
US 20190218257A1 · Romesberg et al. · 2019 [cited by applicant]
US 20190376054A1 · Ptacin et al. · 2019 [cited by applicant]
US 20200017540A1 · Romesberg et al. · 2020 [cited by applicant]
US 20200024597A1 · Ptacin et al. · 2020 [cited by applicant]
US 20200040027A1 · Romesberg et al. · 2020 [cited by applicant]
US 20200095591A1 · Romesberg et al. · 2020 [cited by applicant]
US 20200131555A1 · Ptacin et al. · 2020 [cited by applicant]
EP 0614907A1 · 1994 [cited by applicant]
EP 0629633A2 · 1994 [cited by applicant]
WO WO9414226A1 · 1994 [cited by applicant]
WO WO9422890A1 · 1994 [cited by applicant]
WO WO9735869A1 · 1997 [cited by applicant]
WO WO9914226A2 · 1999 [cited by applicant]
WO WO9962923A2 · 1999 [cited by applicant]
WO WO0105801A1 · 2001 [cited by applicant]
WO WO0132887A1 · 2001 [cited by applicant]
WO WO02070533A2 · 2002 [cited by applicant]
WO WO2004007713A1 · 2004 [cited by applicant]
WO WO2004106356A1 · 2004 [cited by applicant]
WO WO2005021570A1 · 2005 [cited by applicant]
WO WO2005026187A1 · 2005 [cited by applicant]
WO WO2005045015A2 · 2005 [cited by applicant]
WO WO2006049297A1 · 2006 [cited by applicant]
WO WO2007015557A1 · 2007 [cited by applicant]
WO WO2007066737A1 · 2007 [cited by applicant]
WO WO2007134181A2 · 2007 [cited by applicant]
WO WO2008101157A1 · 2008 [cited by applicant]
WO WO2008150729A2 · 2008 [cited by applicant]
WO WO2008154401A2 · 2008 [cited by applicant]
WO WO2009006478A2 · 2009 [cited by applicant]
WO WO2009123216A1 · 2009 [cited by applicant]
WO WO2011043385A1 · 2011 [cited by applicant]
WO WO2011139699A2 · 2011 [cited by applicant]
WO WO2015021432A1 · 2015 [cited by applicant]
WO WO2015157555A2 · 2015 [cited by applicant]
WO WO2016115168A1 · 2016 [cited by applicant]
WO WO2017106767A1 · 2017 [cited by applicant]
WO WO2017223528A1 · 2017 [cited by applicant]
WO WO2019014262A1 · 2019 [cited by applicant]
WO WO2019014267A1 · 2019 [cited by applicant]
WO WO2019133883A1 · 2019 [cited by applicant]
Amman et al., (mBio 7:10.1128/mbio.00999-16, 2016) (Year: 2016). [cited by examiner]
Locey et al., (PNAS 113(21):5970-5975, 2016) (Year: 2016). [cited by examiner]
Arenas-Ramirez et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med 8:367ra166 (Nov. 30, 2016). 13 pages. [cited by applicant]
Bentebibel et al. The Novel IL-2 Cytokine Immune Agonist NKTR-214 Harnesses the Adaptive and Innate Immune System for the Treatment of Solid Cancers. Poster #P77. Society for Immunotherapy of Cancer 2017 Annual Meeting … [cited by applicant]
Bhatt et al. Peripheral Blood Lymphocyte Responses in Patients with Renal Cell Carcinoma treated with High-Dose Interleukin-2. Poster (SITC 2018). [cited by applicant]
Biocentury Innovations publication Oct. 27, 2016 (26 pgs). [cited by applicant]
Boyman et al. Selective Stimulation of T Cell subsets with Antibody-Cytokine Immune Complexes. Science 311:1924-1927 (2006). [cited by applicant]
Boyman et al. Selectively Expanding Subsets of T Cells in Mice by Injection of Interleukin-2/Antibody Complexes: Implications for Transplantation Tolerance. Transplantation Proceedings 44:1032-1034 (2012). [cited by applicant]
Boyman et al. The role of interleukin-2 during homeostatis and activation of the immune system. Nature 12:180-190 (2012). [cited by applicant]
Branca. Rekindling cancer vaccines. Nat Biotechnol 34(10):1019-1025 (2016). [cited by applicant]
Charych et al. Combining Complementary Mechanisms of Immune Activation: NKTR-214, a biased IL-2 Pathway Agonist and Immune Checkpoint Antagonists. Poster Abstract 3018. ESMO Annual Meeting (Oct. 9, 2016, Copenhagen, Den… [cited by applicant]
Charych et al. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Clin Cancer Res 22(3):680-690 (2016) (w/Supplemental Figures). [cited by applicant]
Chastgner et al. Lack of intermediate-affinity interleukin-2 receptor in mice leads to dependence on interkeukin-2 receptor α,β and γ chain expression for T cell growth. Eur J Immunol 26:201-206 (1996). [cited by applicant]
Chatzkel et al. Coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: a single-center, single-arm trial. Poster Abstract No. 244333 (2010). [cited by applicant]
Chen et al. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2. Cell Death& Disease 9:989 (2018). [cited by applicant]
Diab et al. NKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of Pivot. Powerpoint presentation. ClinicalTrials.gov NCT02983045. 2018 ASCO Annual Meeti… [cited by applicant]
Diab et al. Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma… [cited by applicant]
Dranoff. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer 4:11-22 (2004). [cited by applicant]
Floros et al. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol 42(4):539-548 (2015). [cited by applicant]
Gillies et al. A Low-Toxicity IL-2-based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 receptor Selectivity. Clin Cancer Res 17(11):3673-3686 (2011). [cited by applicant]
Heaton et al. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Cell Immunol … [cited by applicant]
Heaton et al. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogu… [cited by applicant]
Hu et al. The Generation of Low Toxicity Interleukin-2 Fusion Proteins Devoid of Vasopermeability Activity. Blood 101(12):4853-61 (2003). [cited by applicant]
Hurwitz et al. A Novel Immune Agonist, NKTR-214, Increases the Number of Activity of CD8+ Tumor Infiltrating Lymphocytes in Patients with Advance Renal Cell Carcinoma. Poster Abstract #454. Poster Session C. ASCO Feb. 1… [cited by applicant]
Insight-Esprit Study Group et al. Interleukin-2 Therapy in Patients with HIV Infection. N Engl J Med. 361(16):1548-59 (2009). [cited by applicant]
Jones et al. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathogens 12(4):e1005545 (2016). [cited by applicant]
Joseph et al. THOR-707, A novel not-alpha IL-2, elicits durable pharmacodynamic responses in non-human primates and, efficacy as single agent and in combination with anti PD-1 in multiple syngeneic mouse models. America… [cited by applicant]
Khalili et al. Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacology. Poster Abstract 1614. AACR Annual Meeti… [cited by applicant]
Kivimäe et al. Comprehensive Antitumor Immune Activation by a Novel TLR 7/8 Targeting Agent NKTR-262 Combined With CD122-Biased Immunostimulary Cytokine NKTR-214. Poster #3755 (AACR Apr. 14-18, 2018). [cited by applicant]
Kivimäe et al. Harnessing the innate and adaptive immune system to eradicate treated and distant untreated solid tumors. Poster #P275. Immunotherapy of Cancer 2017 Annual Meeting (2017). [cited by applicant]
Klein et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.… [cited by applicant]
Krieg et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. PNAS USA 107(26):11906-11911 (Jun. 29, 2010). [cited by applicant]
Langowski et al. The CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of anti-tumor immunity and synergistic activity. Poster Abstract 311. 2016 CR-CIMT-EATIR-AACR… [cited by applicant]
Lazear et al. Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. Oncoimmunology 6(2):e1265721 (2017). [cited by applicant]
Letourneau et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. PNAS USA 107:2171-2176 (2010). [cited by applicant]
Lopes et al. Characterization of the Pharmacodynamic Immune Response to a Novel Immunotherapeutic Agent, ALKS 4230, in Mice and Non-Human Primates. Poster 22 (Abstract #2663) (AACR 2017). [cited by applicant]
Lopes et al. Ex Vivo Expansion and Activation of Human Lymphocytes With a Selective Activator of Effector Cells. Abstract #3158 Poster (AACR 2015). [cited by applicant]
Losey et al. Abstract #4280: Utilizing a Selective Agonist of the Intermediate-Affinity IL-2 Receptor With an Improved Pharmacokinetic Profile Leads to an Enhanced Immunostimulatory Response With Reduced Toxicity in Mic… [cited by applicant]
Losey et al. Efficacy of ALKS 4230, a Novel Immunotherapeutic Agent, in Murine Syngeneic Tumor Models Alone and in Combination with Immune checkpoint Inhibitors. Poster 25 (Abstract #591) (AACR 2017). [cited by applicant]
Losey et al. Utilizing a Selective Agonist of the Intermediate-Affinity IL-2 Receptor With an Improved Pharmacokinetic Profile Leads to an Enhanced Immunostimulatory Response With Reduced Toxicity in Mice. Poster for Ab… [cited by applicant]
Lotze et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865-2875 (1985). [cited by applicant]
Lou et al. Fixing vascular leak in IL-2 immunotherapy. SciBX 3(27):2 pgs (2010). [cited by applicant]
Meghnem et al. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor. J Immunol 198(12):4563-4568 (May 2017). [cited by applicant]
Melero et al. Clinical activity safety, and PK/PD from a Phase 1 study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-cv). ESMO 2018 Congress Poster (Oct. 20, 2018). [cited by applicant]
Merchant et al. Preclinical characterization of IL-2 Superkines engineered with biased CD8+ T cell stimulating properties. Poster (SITC 2018). [cited by applicant]
Milla et al. THOR-707: An engineered IL-2 for the treatment of solid tumors with superior pre-clinical efficacy and safety evidence. 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting Poster (Nov. 9, 20… [cited by applicant]
Milla et al. THOR-707: Using Synthetic Biology to Reprogram the Therapeutic Activity of Interleukin-2 (IL-2). 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Poster (May 15, 2019). [cited by applicant]
Nektak Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting. PRNewswire Nov. 9, 2016. [cited by applicant]
Nektar Therapeutics. Investor Meeting presentation Jun. 3, 2017. [cited by applicant]
Nicolini et al. The FAP-IL2v Immunocytokine is a Versatile Combination Partner for Cancer Immunotherapy. Poster (SITC 2018). [cited by applicant]
Parisi et al. Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214. Poster Abstract #3566. (AACR Apr. 17, 2018). [cited by applicant]
PCT/US2018/045257 International Search Report and Written Opinion dated Nov. 21, 2018. [cited by applicant]
Pfannenstiel et al. A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230. Poster #P351 (SITC 2017). [cited by applicant]
Pieper et al. NKTR-214 in combination with radiation produces a potent in situ vaccine in the syngeneic B78 melanoma model. Poster (STIC 2018). [cited by applicant]
Plieth. Cytokine therapy focus—interleukin-2 claims the early lead. EP Vantage. Evaluate Feb. 27, 2018 (Available at https://www.evaluate.com/vantage/articles/analysis/cytokine-therapy-focus-interleukin-2-claims-early-l… [cited by applicant]
Roessler et al. Cooperative interactions between the interleukin 2 receptor α and β chains later the interleukin 2-binding affinity of the receptor subunits. PNAS USA 91:3344-3347 (1994). [cited by applicant]
Rosentrater et al. Determination of the Relative potency of a Selective Agonist of the Intermediate-Affinity IL-2 Receptor on Lymphocytes from Human, Cynomolgus Monkey and Mouse. Poster for Abstract #4281 (2015). [cited by applicant]
Sharma et al. NKTR-214 enhances anti-tumor T cell immune responses induced by checkpoint blockade or vaccination. Poster (SITC 2017). [cited by applicant]
Siegel et al. Interleukin-2 Toxicity. J Clin Oncol 9(4):694-704 (1991). [cited by applicant]
Sim et al. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunol Res. 4(11):983-995 (Nov. 2016). [cited by applicant]
Sivakumar et al. Comparison of Vascular Leak Syndrome in Mice treated with IL21 or IL2. Comparative Medicine 63(1):13-21 (2013). [cited by applicant]
Spangler et al. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanism. Immunity 42:815-825 (2015). [cited by applicant]
Stauber et al. Crystal Structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. PNAS 103(8):2788-2793 (2006). [cited by applicant]
Sun et al. First-In-Human dose Selection of ALKS 4230, an Investigational Immunotherapeutic Agent. Poster 4088 (AACR 2017). [cited by applicant]
Sun et al. Pharmacokinetics and Pharmacodynamic Effects of ALKS 4230, an Investigational Immunotherapeutic Agent, in Cynomolgus Monkeys After Intravenous and Subcutaneous Administration. Poster (SITC 2018). [cited by applicant]
Synthorx, Inc. Commission File No. 001-38756. Form 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for Fiscal Year End dated Dec. 31, 2018 (144 pgs). [cited by applicant]
Synthorx, Inc. Commission File No. 001-38756. Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for Quarterly Period Ended Mar. 31, 2019. [cited by applicant]
Synthorx, Inc. Commission File No. 001-38756. Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 dated Apr. 2, 2019 (8 pgs). [cited by applicant]
Synthorx, Inc. Commission File No. 001-38756. Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 dated May 31, 2019 (15 pgs). [cited by applicant]
Synthorx, Inc. Registration No. 333-228355. Amendment No. 1 to Form S-1 Registration Statement Under The Securities Act of 1933 filed Nov. 27, 2018 (355 pgs.). [cited by applicant]
U.S. Appl. No. 15/543,217 Office Action dated Apr. 3, 2020. [cited by applicant]
U.S. Appl. No. 15/543,217 Office Action dated Aug. 7, 2019. [cited by applicant]
U.S. Appl. No. 15/543,217 Office Action dated Feb. 7, 2019. [cited by applicant]
U.S. Appl. No. 15/543,217 Office Action dated Nov. 18, 2019. [cited by applicant]
U.S. Appl. No. 15/543,217 Office Action dated Sep. 24, 2018. [cited by applicant]
U.S. Appl. No. 16/413,209, filed May 15, 2019. [cited by applicant]
U.S. Appl. No. 16/413,219, filed May 15, 2019. [cited by applicant]
U.S. Appl. No. 16/434,999, filed Jun. 7, 2019. [cited by applicant]
U.S. Appl. No. 16/518,715, filed Jul. 22, 2019. [cited by applicant]
U.S. Appl. No. 16/530,742, filed Aug. 2, 2019. [cited by applicant]
U.S. Appl. No. 16/535,992, filed Aug. 8, 2019. [cited by applicant]
U.S. Appl. No. 16/546,097, filed Aug. 20, 2019. [cited by applicant]
U.S. Appl. No. 16/546,100, filed Aug. 20, 2019. [cited by applicant]
U.S. Appl. No. 16/577,347, filed Sep. 9, 2020. [cited by applicant]
U.S. Appl. No. 16/591,422, filed Oct. 2, 2019. [cited by applicant]
U.S. Appl. No. 16/839,741, filed Apr. 3, 2020. [cited by applicant]
U.S. Appl. No. 16/900,154, filed Jun. 12, 2020. [cited by applicant]
Vaishampayan et al. A Phase 1 Trial of ALKS 4230, an Engineered Cytokine Activator of NK and Effector T Cells, in Patients with Advanced Solid Tumors. Poster for Abstract #TPS3111 (ASCO 2017). [cited by applicant]
Vaishampayan et al. Safety, pharmacokinetics and pharmacodynamic effects of ALKS 4230 in patients with advanced solid tumors from the ongoing dose escalation portion of a first in human (FIH) study. Poster (SITC 2018). [cited by applicant]
Van Gool et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 124(24):3572-3576 (2014). [cited by applicant]
Van Haelst Pinsani et al. Administration of Interleukin-2 (IL-2) Results in Increased Plasma Concentrations of IL-5 and Eosinophilia in Patients with Cancer. Blood 78:1538-1544 (1991). [cited by applicant]
Vazquez-Lombardi et al. Potent antitumour activity of the interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells. Nat Comm 8:15373 (2017). [cited by applicant]
Waldmann et al. The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy. Cancer Immunol Res 3(3):219-227 (2015). [cited by applicant]
Walker et al. Combination of NKTR-214 and Radiotherapy (RT) to reverse anergy and expand specific CD8 T cells. Poster (SITC 2017). [cited by applicant]
Wang et al. Enhanced Anti-tumor Activity of the Combination of Entinostat and NKTR-214 in Renal and Colon Cancer Tumor Models. Poster. AACR Annual Meeting 2018 (AACR 2018). [cited by applicant]
Wang et al. Structure of the Quaternary Complex of Interleukin-2 with Its α, β, and γc Receptors. Science 310:1159-63 (2005). [cited by applicant]
Webster et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Med Chem 206(4):751-760 (2009). [cited by applicant]
Yamaguchi et al. Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2. J Immunol 145:873-877 (1990). [cited by applicant]
Zalevsky. Jefferies 2016 Global Healthcare Conference. PowerPoint presentation (Nov. 16, 2016). [cited by applicant]
Adhikary et al. Adaptive Mutations Alter Antibody Structure and Dynamics During Affinity Maturation. Biochemistry 54(11):2085-93 (2015). [cited by applicant]
Ambrogelly et al. Pyrrolysine is not hardwired for cotranslational insertion at UAG condons. PNAS 104(9):3141-3146 (2007). [cited by applicant]
Amiri et al. Deep origin of plastid/parasite ATP/ADP translocases. J. Mol. Evol. 56:137-150 (2003). [cited by applicant]
Ast et al. Diatom plastids depend on nucleotide import from the cytosol. PNAS USA 106:3621-3626 (2009). [cited by applicant]
Beigelman et al. Synthesis of 5′-C-Methyl-D-allo- & L-Talo-ribonucleoside 3′ -O-Phosphoramidites & Their Incorporation into Hammerhead Ribozymes. Nucleosides and Nucleotides 14(3-5):901-905 (1995). [cited by applicant]
Berger et al. Stability and selectivity of unnatural DNA with five-membered-ring nucleobase analogues. J Am Chem Soc 124(7):1222-6 (2002). [cited by applicant]
Berger et al. Stable and selective hybridization of oligonucleotides with unnatural hydrophobic bases. Angew Chem Int Ed Engl 39:2940-2942 (2000). [cited by applicant]
Berger et al. Universal bases for hybridization, replication and chain termination. Nucleic Acids Res 28(15):2911-2914 (2000). [cited by applicant]
Betz et al. KlenTaq polymerase replicates unnatural base pairs by inducing a Watson-Crick geometry. Nat Chem Biol 8:612-614 (2012). [cited by applicant]
Betz et al. Structural insights into DNA replication without hydrogen bonds. J Am Chem Soc 135:18637-18643 (2013). [cited by applicant]
Bohringer et al. Synthesis of 5′-deoxy-5′-methylphosphonate linked thymidine oligonucleotides. Tet Lett 34:2723-2726 (1993). [cited by applicant]
Bordo et al. Suggestions for “safe” residue substitutions in site-directed mutagenesis. J Mol Biol 217:721-729 (1991). [cited by applicant]
Braasch et al. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Bio 8:1-7 (2001). [cited by applicant]
Cann et al. A heterodimeric DNA polymerase: Evidence that members of Euryarchaeota possess a distinct DNA polymerase. PNAS USA 95:14250 (1998). [cited by applicant]
Cariello et al. Fidelity of Thermococcus litoralis DNA polymerase (VentTM) in PCR determined by denaturing gradient gel electrophoresis Nucl Acid Res 19:4193-4198 (1991). [cited by applicant]
Chatterjee et al. A Versatile Platform for Single- and Multiple-Unnatural Amino Acid Mutagenesis in [cited by applicant]
Chaturvedi et al. Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages. Nucleic Acids Res. 24:2318-2323 (19… [cited by applicant]
Chen et al. Directed polymerase evolution. FEBS Lett. 588(2):219-229 (2014). [cited by applicant]
Chen et al. Phosphonate Analogues of Cytosine Arabinoside Monophosphate. Phosphorus, Sulfur and Silicon 177:1783-1786 (2002). [cited by applicant]
Chen et al. The expanding world of DNA and RNA. Curr Opin Chem Biol 34:80-87 (2016). [cited by applicant]
Chien et al. Deoxyribonucleic acid polymerase from the extreme thermophile Thermus aquaticus. J Bacteriol 127:1550-1557 (1976). [cited by applicant]
Collingwood et al. The Synthesis and Incorporation in Oligonucleotides of a Thymidine Dimer Containing an Internucleoside Phosphinate Linkage. Synlett 7:703-705 (1995). [cited by applicant]
Crooke et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277:923-937 (1996). [cited by applicant]
De Mesmaeker et al. Amide-Modified Oligonucleotides with Preorganized Backbone and Furanose Rings: Highly Increased Thermodynamic Stability of the Duplexes Formed with their RNA and DNA Complements. Synlett 1997(11)1287… [cited by applicant]
Dhami et al. Systematic exploration of a class of hydrophobic unnatural base pairs yields multiple new candidates for the expansion of the genetic alphabet. Nucleic Acids Res 42:10235-10244 (2014). [cited by applicant]
Diaz et al. Accuracy of replication in the polymerase chain reaction. Comparison between Thermotoga maritima DNA polymerase and Thermus aquaticus DNA polymerase. Braz J Med Res 31:1239-1242 (1998). [cited by applicant]
Dien et al. Eight-Letter DNA. Biochemistry 58:2581-2583 (2019). [cited by applicant]
Dien et al. Expansion of the genetic code via expansion of the genetic alphabet. Curr Opin Chem Biol 46:196-202 (2018). [cited by applicant]
Dien et al. Progress Toward a Semi-Synthetic Organism with an Unrestricted Expanded Genetic Alphabet. J Am Chem Soc. 140:16115-16123 (2018). [cited by applicant]
Dupradeau et al. Differential solvation and tautomer stability of a model base pair within the minor and major grooves of Dna. J Am Chem Soc 127(44): 15612-7 (2005). [cited by applicant]
Elayadi et al. Application of PNA and LNA oligomers to chemotherapy. Curr Opinion Invens Drugs 2:558-561 (2001). [cited by applicant]
Ellington et al. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822 (1990). [cited by applicant]
Englisch et al. Chemically Modified Oligonucleotides as Probes and Inhibitors. Angew. Chem. Int. Ed. Eng. 30:613-629 (1991). [cited by applicant]
Eppacher et al. Synthesis and Incorporation of C(5′)-Ethynylated Uracil-Derived Phosphoramidites into RNA. Helvetica Chimica Acta 87:3004-3020 (2004). [cited by applicant]
Fa et al. Expanding the substrate repertoire of a DNA polymerase by directed evolution. J Am Chem Soc 126(6):1748-54 (2004). [cited by applicant]
Fairhurst et al. Synthesis and Hybridisation Properties of Phosphonamidate Ester Modified Nucleic Acid. Synlett 4:467-472 (2001). [cited by applicant]
Fan et al. Rationally evolving tRNAPyl for efficient incorporation of noncanonical amino acids. Nucleic Acids Res 43(22):e156 (2015). [cited by applicant]
Feldman et al. A Tool for the Import of Natural and Unnatural Nucleoside Triphosphates into Bacteria. J Am Chem Soc 140(4):1447-1454 (2018). [cited by applicant]
Feldman et al. Chemical Stabilization of Unnatural Nucleotide Triphosphates for the in Vivo Expansion of the Genetic Alphabet. J Am Chem Soc 139(6):2464-2467 (2017). [cited by applicant]
Feldman et al. In Vivo Structure-Activity Relationships and Optimization of an Unnatural Base Pair for Replication in a Semi-Synthetic Organism. J Am Chem Soc 139:11427-11433 (2017). [cited by applicant]
Feldman et al. Optimization of Replication, Transcription, and Translation in a Semi-Synthetic Organism. J Am Chem Soc 141:10644-10653 (2019). [cited by applicant]
Feldman. Expansion of the Genetic Alphabet: A Chemist's Approach to Synthetic Biology. Acc Chem Res 51(2):394-403 (2018). [cited by applicant]
Gallier et al. Ex-Chiral-Pool Synthesis of β-Hydroxyphosphonate Nucleoside Analogues. Eur J Org Chem 6:925-933 (2007). [cited by applicant]
Gardner et al. Comparative Kinetics of Nucleotide Analog Incorporation by Vent DNA Polymerase. J Biol Chem 279(12):11834-11842 (2004). [cited by applicant]
Gardner et al. Determinants of nucleotide sugar recognition in an archaeon DNA polymerase. Nucleic Acids Research 27(12):2545-2553 (1999). [cited by applicant]
Geze et al. Synthesis of sinefungin and its C-6′ epimer. J Am Chem Soc 105(26):7638-7640 (1983). [cited by applicant]
Haferkamp et al. Functional expression and characterisation of membrane transport proteins. Plant Biol. 14:675-690 (2012). [cited by applicant]
Haferkamp et al. Tapping the nucleotide pool of the host: novel nucleotide carrier proteins of Protochlamydia amoebophila. Mol. Microbiol. 60:1534-1545 (2006). [cited by applicant]
Hampton et al. Design of substrate-site-directed inhibitors of adenylate kinase and hexokinase. Effect of substrate substituents on affinity on affinity for the adenine nucleotide sites. J Med Chem 19:1371-1377 (1976). [cited by applicant]
Hampton et al. Design of substrate-site-directed irreversible inhibitors of adenosine 5′-phosphate aminohydrolase. Effect of substrate substituents on affinity for the substrate site. J Med Chem 19(8):1029-1033 (1976). [cited by applicant]
Hampton et al. Synthesis of 6′-cyano-6′-deoxyhomoadenosine-6′-phosphonic acid and its phosphoryl and pyrophosphoryl anhydrides and studies of their interactions with adenine nucleotide utilizing enzymes. J Am Chem Soc 9… [cited by applicant]
Hancock et al. Expanding the Genetic Code of Yeast for Incorporation of Diverse Unnatural Amino Acids via a Pyrrolysyl-tRNA Synthetase/tRNA Pair. JACS 132:14819-14824 (2010). [cited by applicant]
Hari et al. Optimization of the pyridyl nucleobase scaffold for polymerase recognition and unnatural base pair replication. Chembiochem 9(17):2796-2799 (2008). [cited by applicant]
Hatch et al. Adenine nucleotide and lysine transport in Chlamydia psittaci. J. Bacteriol. 150:662-670 (1982). [cited by applicant]
Hayes et al. Combining computational and experimental screening for rapid optimization of protein properties. PNAS USA 99:15926-15931 (2002). [cited by applicant]
Henry et al. Beyond A, C, G and T: augmenting nature's alphabet. Curr Opin Chem Biol 7(6):727-33 (2003). [cited by applicant]
Henry et al. Determinants of unnatural nucleobase stability and polymerase recognition. J Am Chem Soc 125(32):9638-9646 (2003). [cited by applicant]
Henry et al. Efforts to expand the genetic alphabet: identification of a replicable unnatural DNA self-pair. J Am Chem Soc 126(22):6923-31 (2004). [cited by applicant]
Hinnisdaels et al. Direct cloning of PCR products amplified with Pwo DNA polymerase. Biotechniques 20:186-188 (1996). [cited by applicant]
Hirao et al., Unnatural base pair systems toward the expansion of the genetic alphabet in the central dogma. Proceedings of the Japan Academy, Series B, Phys Biol Sci. 88:345-367 (2012). [cited by applicant]
Horn et al. Bacterial endosymbionts of free-living amoebae. J. Eukaryot. Microbiol. 5:509-514 (2004). [cited by applicant]
Hutter et al. From Phosphate to Bis(methylene) Sulfone: Non-Ionic Backbone Linkers in DNA. Helvetica Chimica Acta 85:2777-2806 (2002). [cited by applicant]
Hwang et al. Polymerase recognition and stability of fluoro-substituted pyridone nucleobase analogues. Chembiochem 8:1606-1611 (2007). [cited by applicant]
Hwang et al. Substituent effects on the pairing and polymerase recognition of simple unnatural base pairs. Nucleic Acids Res 34(7):2037-45 (2006). [cited by applicant]
Hwang et al. The effects of unnatural base pairs and mispairs on DNA duplex stability and solvation. Nucleic Acids Res 37(14):4757-4763 (2009). [cited by applicant]
Hwang et al. Unnatural substrate repertoire of A, B, and X family DNA polymerases. J Am Chem Soc 130(44):14872-14882 (2008). [cited by applicant]
Jager et al. Oligonucleotide N-alkylphosphoramidates: synthesis and binding to polynucleotides. Biochemistry 27:7247-7246 (1988). [cited by applicant]
Jinek et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816-821 (2012). [cited by applicant]
Juncosa-Ginesta et al. Improved efficiency in site-directed mutagenesis by PCR using a [cited by applicant]
Jung et al. Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. Bioorg Med Chem 8:2501-2509 (2000). [cited by applicant]
Kabanov et al. A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells. FEBS … [cited by applicant]
Kandimalla et al. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg. Med. Chem. 9:807-813 (2001). [cited by applicant]
Kappler et al. Isozyme-specific enzyme inhibitors. 11. L-homocysteine-ATP S-C5′ covalent adducts as inhibitors of rat methionine adenosyltransferases. J Med Chem 29:1030-1038 (1986). [cited by applicant]
Kappler et al. Species- or isozyme-specific enzyme inhibitors. 8. Synthesis of disubstituted two-substrate condensation products as inhibitors of rat adenylate kinases. J Med Chem 25:1179-1184 (1982). [cited by applicant]
Kim et al. Stability and polymerase recognition of pyridine nucleobase analogues: role of minor-groove H-bond acceptors. Angew Chem Int Ed Engl 45(46):7809-12 (2006). [cited by applicant]
Koshkin et al. LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrah… [cited by applicant]
Kumar et al. The First Analogues of LNA (Locked Nucleic Acids): Phosphorothioate LNA and 2′-Thio-LNA. Bioorg Med Chem Lett 8:2219-2222 (1998). [cited by applicant]
Lavergne et al. Expanding the scope of replicable unnatural DNA: Stepwise optimization of a predominantly hydrophobic base pair. JACS 135:5408-5419 (2013). [cited by applicant]
Lavergne et al. FRET Characterization of Complex Conformational Changes in a Large 16S Ribosomal RNA Fragment Site-Specifically Labeled Using Unnatural Base Pairs. ACS Chem Biol 11(5):1347-53 (2016). [cited by applicant]
Lavergne et al. Major groove substituents and polymerase recognition of a class of predominantly hydrophobic unnatural base pairs. Chem. Eur. J. 18:1231-1239 (2012). [cited by applicant]
Lecomte et al. Selective Inactivation of the 3′ to 5′ exonuclease activity of [cited by applicant]
Leconte et al. Amplify this! DNA and RNA get a third base pair. Nat Meth 3:667-668 (2006). [cited by applicant]
Leconte et al. An efficiently extended class of unnatural base pairs. J Am Chem Soc 128(21):6780-1 (2006). [cited by applicant]
Leconte et al. Chemical biology: a broader take on DNA. Nature 444:553-555 (2006). [cited by applicant]
Leconte et al. Directed Evolution of DNA Polymerases for Next-Generation Sequencing. Angew Chem Int Ed Engl 49(34):5921-5924 (2010). [cited by applicant]
Leconte et al. Discovery, characterization, and optimization of an unnatural base pair for expansion of the genetic alphabet. J Am Chem Soc 130(7):2336-2343 (2008). [cited by applicant]
Leconte et al. Efforts towards expansion of the genetic alphabet: pyridone and methyl pyridone nucleobases. Angew Chem Int Ed Engl 45(26):4326-9 (2006). [cited by applicant]
Leconte et al. Polymerase evolution: efforts toward expansion of the genetic code. J Am Chem Soc 127(36):12470-1 (2005). [cited by applicant]
Ledbetter et al. Editorial overview: Expanding the genetic alphabet and code. Curr Opin Chem Biol 46:A1-A2 (2018). [cited by applicant]
Ledbetter et al. Reprograming the Replisome of a Semisynthetic Organism for the Expansion of the Genetic Alphabet. J Am Chem Soc. 140:758-765 (2018). [cited by applicant]
Ledbetter et al. Site-Specific Labeling of DNA via PCR with an Expanded Genetic Alphabet. Methods Mol Biol 1973:193-212 (2019). [cited by applicant]
Letsinger et al. Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. PNAS 86:6553-6556 (1989). [cited by applicant]
Levin. It's prime time for reverse transcriptase. Cell 88:5-8 (1997). [cited by applicant]
Li et al. Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension. Bioconjugate Chem 30:1232-1243 (2019). [cited by applicant]
Li et al. Natural-like Replication of an Unnatural Base Pair for the Expansion of the Genetic Alphabet and Biotechnology Applications. J Am Chem Soc 136:826-829 (2014). [cited by applicant]
Li et al. Site-Specifically Arraying Small Molecules or Proteins on DNA Using An Expanded Genetic Alphabet. Chem Eur J 19:14205-14209 (2013). [cited by applicant]
Lundberg et al. High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus. Gene 108:1-6 (1991). [cited by applicant]
Malyshev et al. A semi-synthetic organism with an expanded genetic alphabet. Nature 509(7500):385-388 (2014). [cited by applicant]
Malyshev et al. Efficient and sequence-independent replication of DNA containing a third base pair establishes a functional six-letter genetic alphabet. PNAS USA 109:12005-12010 (2012). [cited by applicant]
Malyshev et al. PCR with an Expanded Genetic Alphabet. JACS 131(41):14620-14621 (2009). [cited by applicant]
Malyshev et al. Solution structure, mechanism of replication, and optimization of an unnatural base pair. Chem Eur J 16:12650-12659 (2010). [cited by applicant]
Manoharan et al. Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides. Ann. N.Y. Acad. Scie 660:306-309 (1992). [cited by applicant]
Manoharan et al. Cholic Acid-Oligonucleotide Conjugates for Antisense Applications. Bioorg. Med. Chem. Let 4:1053-1060 (1994). [cited by applicant]
Manoharan et al. Introduction of a Lipophilic Thioether in the Minor Groove of Nucleic Acids for Antisense Applications. Bioorg. Med. Chem. Let 3:2765-2770 (1993). [cited by applicant]
Manoharan et al. Lipidic Nucleic Acids. Tetrahedron Lett 36:3651-3654 (1995). [cited by applicant]
Manoharan et al. Oligonucleotide Conjugates: Alteration of the Pharmacokinetic Properties of Antisense Agents. Nucleosides & Nucleotides 14:969-973 (1995). [cited by applicant]
Matsuda et al. Efforts toward expansion of the genetic alphabet: structure and replication of unnatural base pairs. J Am Chem Soc 129(34):10466-73 (2007). [cited by applicant]
Matsuda et al. Minor groove hydrogen bonds and the replication of unnatural base pairs. J Am Chem Soc 129(17):5551-7 (2007). [cited by applicant]
Matsuda et al. Optimization of interstrand hydrophobic packing interactions within unnatural DNA base pairs. J Am Chem Soc 126(44):14419-27 (2004). [cited by applicant]
Matsuda et al. Optimization of unnatural base pair packing for polymerase recognition. J Am Chem Soc 128(19):6369-75 (2006). [cited by applicant]
Matsuda et al. The effect of minor-groove hydrogen-bond acceptors and donors on the stability and replication of four unnatural base pairs. J Am Chem Soc 125(20):6134-9 (2003). [cited by applicant]
Matteucci. Oligonucleotide Analogs: an Overview in Oligonucleotides as Therapeutic Agents, (Chadwick and Cardew, ed.) John Wiley and Sons, New York, NY; Zon, 1993, Oligonucleoside Phosphorothioates in Protocols for Olig… [cited by applicant]
McMinn et al. Efforts toward Expansion of the Genetic Alphabet: DNA Polymerase Recognition of a Highly Stable, Self-Pairing Hydrophobic Base. J. Am. Chem. Soc. 121:11585-11586 (1999). [cited by applicant]
Meggers et al. A Novel Copper-Mediated DNA Base Pair. J. Am. Chem. Soc. 122:10714-10715 (2000). [cited by applicant]
Micklefield. Backbone Modification of Nucleic Acids: Synthesis, Structure and Therapeutic Applications. Current Medicinal Chemistry 8:1157-1179 (2001). [cited by applicant]
Mikhailov et al. Substrate Properties of C′-Methylnucleoside and C′-Methyl-2′-deoxynucleoside 5′-Triphosphates in RNA and DNA Synthesis Reactions Catalysed by RNA and DNA Polymerases Nucleosides & Nucleotides 10(1-3):33… [cited by applicant]
Miller et al. Conformation and interaction of dinucleoside mono- and diphosphates. V. Syntheses and properties of adenine and thymine nucleoside alkyl phosphotriesters, the neutral analogs of dinucleoside monophosphates… [cited by applicant]
Miroux et al. Over-production of proteins in [cited by applicant]
Mishra et al. Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery. Biochem Biophys Acta 1264:229-237 (1995). [cited by applicant]
Morris et al. Synthetic Biology Parts for the Storage of Increased Genetic Information in Cells. ACS Synth Biol 6(10):1834-1840 (2017). [cited by applicant]
Myers et al. Reverse transcription and DNA amplification by a Thermus thermophilus DNA polymerase. Biochemistry 30:7661-7666 (1991). [cited by applicant]
Nawrot et al. A novel class of DNA analogs bearing 5′-C-phosphonothymidine units: synthesis and physicochemical and biochemical properties. Oligonucleotides16(1):68-82 (2006). [cited by applicant]
Nelson et al. N3′-- > P5′ Oligodeoxyribonucleotide Phosphoramidates: A New Method of Synthesis Based on a Phosphoramidite Amine-Exchange Reaction. J Org Chem 62:7278-7287 (1997). [cited by applicant]
Nguyen et al. Genetic Encoding and Labeling of Aliphatic Azides and Alkynes in Recombinant Proteins via a Pyrrolysyl-tRNA Synthetase/tRNACUA Pair and Click Chemistry. JACS 131:8720-8721 (2009). [cited by applicant]
Nielsen et al. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254:1497-1500 (1991). [cited by applicant]
Nordstrom et al. Characterization of bacteriophage T7 DNA polymerase purified to homogeneity by antithioredoxin immunoadsorbent chromatography. J Biol Chem 256:3112-3117 (1981). [cited by applicant]
Oberhauser et al. Effective incorporation of 2′-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol. Nucl. Acids Res. 20:533-538 (1992). [cited by applicant]
Ogawa et al. Efforts toward the Expansion of the Genetic Alphabet: Information Storage and Replication with Unnatural Hydrophobic Base Pairs. J. Am. Chem. Soc. 122:3274-3278 (2000). [cited by applicant]
Ogawa et al. Rational Design of an Unnatural base Pair with Increased Kinetic Selectivity. J. Am. Chem. Soc. 122:8803-8804 (2000). [cited by applicant]